Trial Enrollment Information
Delcath has commenced a global Phase 2 clinical trial in Europe and the U.S. to investigate the Melphalan/HDS for the treatment of primary liver cancer (hepatocellular carcinoma or HCC). We are also initiating a cohort within the global phase 2 clinical trial to evaluate patients with intrahepatic cholangiocarcinoma (ICC). We are also advancing plans to conduct a global Phase 3 trial in ocular melanoma that has metastasized to the liver.
Delcath does not make any claim whatsoever, real or implied, about the efficacy or safety of any therapy, drug, system, or technique under active research.